Filing Flows › Mirum Pharmaceuticals (MIRM) › Q1 2025
Mirum Pharmaceuticals (MIRM) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 7, 2025
Mirum Pharmaceuticals (MIRM) reported revenue of $112M for the first quarter 2025 (Q1 2025), +61% from a year earlier and +12% from the quarter before. Operating margin was -13.6%, net loss $14.7M (13.2% of revenue).
Mirum Pharmaceuticals, Q1 2025: revenue $112M (+61% year over year), operating margin -13.6%, net loss $14.7M, operating cash flow −$2.0M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $112M | +12% | +61% |
| Operating profit | −$15.2M | — | — |
| Net earnings | −$14.7M | — | — |
| Operating cash flow | −$2.0M | — | — |
What changed
Revenue was $111.6M in Q1 2025, up 61% year over year and up 12% from the previous quarter. Livmarli was the largest line at 66% of revenue. Livmarli added $30.4M year over year (up 71%), 72% of the total change.
Operating costs exceeded revenue by $15.2M, an operating margin of -13.6%. Total costs grew 32% against revenue growth of 61%. The fastest-growing cost line was Research & development (+43%). The quarter ended with a net loss of $14.7M, narrower than the previous quarter's $23.8M loss.
Operating cash flow was −$2.0M. Non-cash charges added back $6.1M of depreciation and amortization and $15.8M of share-based compensation. Working capital and other items used $9.1M. Capital expenditures of $41K exceeded it, leaving free cash flow of −$2.0M.
Questions
What was Mirum Pharmaceuticals' revenue in the first quarter 2025?
Mirum Pharmaceuticals (MIRM) reported revenue of $112M for the first quarter 2025 (Q1 2025), +61% from a year earlier and +12% from the quarter before.
Was Mirum Pharmaceuticals profitable in the first quarter 2025?
Operating loss was $15.2M (-13.6% of revenue) and net loss $14.7M.